For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the existing trade environment and doesn't reflect any trade-policy shifts, including pharmaceutical-sector tariffs.

Q1 2025 Management View CEO Rob Michael highlighted an excellent start to 2025, with adjusted EPS of $2.46, exceeding the guidance midpoint by $0.10, and total revenues surpassing $13.3 billion, driven by a 21% growth in the ex-Humira platform.